BCL2 and ovarian carcinoma: showed that MDR1 and BCL2 siRNA‐loaded PLGA nanoparticles suppressed the expression of MDR1 and BCL2 in ovarian cancer cells, and this suppression overcame the chemoresistance of paclitaxel and cisplatin [37].